Natural killer cell

Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology

Retrieved on: 
Monday, December 19, 2022

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKETTM (Antibody-based NK Cell Engager Therapeutics) platform.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKETTM (Antibody-based NK Cell Engager Therapeutics) platform.
  • “At Sanofi, we are exploring the potential of NK cells for cancer immunotherapy, a key pillar for our oncology strategy.
  • ANKETTM (Antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.
  • At Sanofi, we are exploring the intrinsic abilities of Natural Killer cells to create new immunotherapies for patients with cancer.

INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™

Retrieved on: 
Thursday, December 8, 2022

Persistent tumor killing memory-like NK cells in the patient with MDS for more than 100 days.

Key Points: 
  • Persistent tumor killing memory-like NK cells in the patient with MDS for more than 100 days.
  • “The treatment of these patients with advanced hematologic malignancies has produced proof-of-concept data for INKmune while expanding insight into the role of NK cells in controlling cancer,” said Dr. Mark Lowdell, CSO of INmune Bio.
  • Tumor-primed NK (TpNK) cells can lyse a wide variety of NK-resistant tumors including leukemias, lymphomas, myeloma, ovarian cancer, breast cancer.
  • The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer.

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer

Retrieved on: 
Tuesday, December 6, 2022

Boca Raton, Florida, Dec. 06, 2022 (GLOBE NEWSWIRE) --   INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, has been invited to present data on the combination of INB03™ and trastuzumab-deruxtecan (TDxd) for treatment of HER2 positive breast cancer. The data suggests INB03™, a dominant-negative TNF inhibitor that selectively sequesters soluble TNF (sTNF), may provide a novel mechanism for reversing resistance to HER2 targeted immunotherapy, and through this mechanism, may further enhance efficacy and reduce toxicity associated with TDxd treatment in some patients. TDxd is a trastuzumab-based antibody drug conjugate used to treat certain patients with HER2 breast cancer.

Key Points: 
  • “MUC4 expression is an easily determined biomarker that predicts resistance to trastuzumab based immunotherapy.
  • INmune Bio, Inc . is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
  • DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™).
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.

Natural Killer Cells Therapeutics Global Market Report 2022: Increasing Applications in the Treatment of Critical Diseases Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 14, 2022

The global natural killer cells therapeutics market is anticipated to witness an impressive growth during the forecast period.

Key Points: 
  • The global natural killer cells therapeutics market is anticipated to witness an impressive growth during the forecast period.
  • Increasing application of natural killer cells for the treatment of various disease including liver diseases, infections, cancer, among others is expected to drive the growth of global natural killer cells therapeutics market in the forecast period.
  • All these benefits associated with natural killer cells is expected to drive the growth of global natural killer cells therapeutics market during the forecast period.
  • In this report, global natural killer cells therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
    Natural Killer Cells Therapeutics Market, By Type:
    Natural Killer Cells Therapeutics Market, By Application:

INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments

Retrieved on: 
Tuesday, November 29, 2022

Boca Raton, Florida, Nov. 29, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease will participate in the 15th CTAD Conference in San Francisco November 29th to December 2nd.

Key Points: 
  • This years CTAD is showcasing a potential approvable therapy for the treatment of Alzheimers Disease (AD) that targets amyloid, said RJ Tesi MD, CEO of INmune.
  • This will require the incorporation of novel biomarkers into innovative clinical trial designs.
  • Novel, non-invasive neuroimaging biomarkers are used to demonstrate biologic effects of XPro therapy in AD patients with neuroinflammation.
  • is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.

INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease

Retrieved on: 
Monday, November 14, 2022

We are pleased that Canada is now part of this international Phase II trial, said Dr. RJ Tesi, CEO of INmune Bio.

Key Points: 
  • We are pleased that Canada is now part of this international Phase II trial, said Dr. RJ Tesi, CEO of INmune Bio.
  • Enrolling patients in both Canada and Australia gives us access to a larger patient population that should help increase the pace of enrollment.
  • The first patient in the Phase 2 trial recently completed all dosing and has enrolled in an open-label extension study in Australia.
  • DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03), Mild Alzheimers disease, Mild Cognitive Impairment and treatment-resistant depression (XPro).

Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting

Retrieved on: 
Monday, November 7, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of two preclinical data abstracts focused on its natural killer cell pipeline and proprietary manufacturing technology at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting and Pre-Conference Programs.

Key Points: 
  • "Our presentations at this year's SITC meeting illustrate the inherent power and potential of donor-derived NK cells, said James Trager, PhD, Chief Scientific Officer of Nkarta.
  • Nkartas research team has shown that our manufacturing platform technology can expand NK cells by well over a billion-fold, while maintaining their integrity and potency.
  • In a second study, the team has also further built on the considerable potency of our CD19-directed CAR NK candidate, NKX019.
  • Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients.

Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting

Retrieved on: 
Monday, November 7, 2022

SHANGHAI and HONG KONG, Nov. 6, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, today announced that it will present updated results from the Phase Ib TOUCH study of selinexor for treatment of R/R T and NK-cell lymphoma in a poster at the upcoming 2022 American Society of Hematology (ASH) Annual Meeting. In addition, preliminary results from the investigator-initiated LAUNCH trial will be published in an on-line abstract. The 2022 ASH Annual Meeting will be held virtually and in person in New Orleans, Louisiana, the United States, from December 10-13, 2022.

Key Points: 
  • In addition, preliminary results from the investigator-initiated LAUNCH trial will be published in an on-line abstract.
  • The 2022 ASH Annual Meeting will be held virtually and in person in New Orleans, Louisiana, the United States, from December 10-13, 2022.
  • "The data to be presented at ASH 2022 highlights the broad clinical potential and manageable side effect profile of selinexor in patients with well-defined T-cell lymphomas and R/R MM," said Dr. Jay Mei, Antengene's Founder, Chairman and CEO.
  • "It is our great pleasureto share these updates with the hematology/oncology community at ASH 2022."

INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Retrieved on: 
Wednesday, November 2, 2022

BOCA RATON, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the Company), a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, today reported its financial results for the quarter ended September 30, 2022 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the Company), a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, today reported its financial results for the quarter ended September 30, 2022 and provides a business update.
  • The second UK clinical site is due to be initiated in November 2022 and a third UK site is under evaluation.
  • Financial Results for the Quarter Ended September 30, 2022:
    Net loss attributable to common stockholders for the quarter ended September 30, 2022 was approximately $7.7 million, compared to approximately $9.5 million for the quarter ended September 30, 2021.
  • Other expense was approximately $0.3 million for the quarter ended September 30, 2022 compared to approximately $0.4 million during the quarter ended September 30, 2021.

INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2

Retrieved on: 
Wednesday, October 26, 2022

Boca Raton, Florida, Oct. 26, 2022 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Wednesday, November 2, 2022 at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2022 and to provide a corporate update.

Key Points: 
  • A replay will also be available through November 9 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no.
  • is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.
  • The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.